U.S., Oct. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07220629) titled 'Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)' on Oct. 17.
Brief Summary: A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
Study Start Date: Oct. 02
Study Type: INTERVENTIONAL
Condition:
Obesity
Intervention:
DRUG: NT-0796
Orally administered capsules
DRUG: Placebo
Orally administered capsules
Recruitment Status: RECRUITING
Sponsor: NodThera Limited
Published by HT Digi...